TLSA Stock Overview
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Tiziana Life Sciences Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.78 |
| 52 Week High | US$1.27 |
| 52 Week Low | US$0.41 |
| Beta | 0.23 |
| 1 Month Change | 71.08% |
| 3 Month Change | 37.14% |
| 1 Year Change | -10.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.33% |
Recent News & Updates
Recent updates
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?
Sep 19
We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate
Jun 03Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?
Jan 16Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy
Oct 12Tiziana chief medical officer further increases holdings in company
Sep 23Tiziana Life Sciences executive chairman further raises stake in company
Sep 16Tiziana executive chairman raises stake in company again, buys more shares
Aug 25Tiziana Life Sciences discloses share purchase by executive chairman
Aug 17Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?
Aug 15Tiziana Life Sciences CEO Kunwar Shailubhai resigns
Jul 15Shareholder Returns
| TLSA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 51.1% | 1.5% | 1.2% |
| 1Y | -10.9% | 1.1% | 24.7% |
Return vs Industry: TLSA underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: TLSA underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| TLSA volatility | |
|---|---|
| TLSA Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLSA's share price has been volatile over the past 3 months.
Volatility Over Time: TLSA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 9 | Gabriele Marco Cerrone | www.tizianalifesciences.com |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients.
Tiziana Life Sciences Ltd Fundamentals Summary
| TLSA fundamental statistics | |
|---|---|
| Market cap | US$77.74m |
| Earnings (TTM) | -US$19.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.0x
P/E RatioIs TLSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLSA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.50m |
| Earnings | -US$19.50m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TLSA perform over the long term?
See historical performance and comparison